News of the Day

The over-hyped response to PhRMA's submission to the United States Trade Representative's Special 301 process has been exposed for the nonsense it was with the release of the 2025 National Trade Estimate.

The company said it created the council to improve health outcomes for Aboriginal and Torres Strait Islander peoples living with diabetes, obesity, and related chronic conditions.

Christina Xinos, the medical director for Ipsen Australia, said, “We believe that this development demonstrates the rare focus we have on providing solutions for people living with cholestatic liver disease and improving patient outcomes.”

Announcing the PBS reimbursement, Andrew Thomas, GSK Australia vice president and general manager, said, “After being introduced internationally, we are thrilled to finally bring OMJJARA ‘home’ and remain enormously proud of our contribution and of the teams who have made this happen."

Nicole Gaupset, the general manager of Alexion, AstraZeneca Rare Disease, Australasia, said, “Alexion is delighted that the Australian Government has acknowledged the profound impact of this disease by listing Ultomiris on the PBS.”

BioNSW has launched its inaugural BioInvest Catalyst event. The organisation said the three-part event series aims to foster deeper engagement between investors and life science entrepreneurs.

The Boehringer Ingelheim Australia and New Zealand general manager, Ed Hollywood, said, “Managing cardiovascular risk is a critical element of diabetes care. Ultimately, the goal is to prevent cardiovascular events and deaths."

The Budget included over $1 billion in funding decisions taken but not yet announced and around the same amount in future savings measures. The details of these decisions and measures will be announced by the Albanese Government this week or released as part of PEFO next week.

A new Australian Institute of Health and Welfare report has revealed the emerging impact of the changes to make treatment for opiate dependence more affordable and accessible.

US criticism of the PBS is like catnip for some people, they can't resist it, even if it's the same criticism articulated by multiple Australian stakeholders and the health minister. The strange secrecy over the government's review of arrangements for blood supply products and the terrible treatment of a female academic leader.

The work of the Health Technology Assessment Review Implementation Advisory Group will continue during the election caretaker period.